Tenaya Therapeutics (TNYA) Accounts Payables (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Accounts Payables of $1.9 million for Q1 2026, down 62.2% year-over-year from $5.1 million in Q1 2025, and down 46.55% quarter-over-quarter from $3.6 million in Q4 2025.
Tenaya Therapeutics (TNYA) Accounts Payables (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 62.2% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 62.2% YoY), while the FY2025 annual figure was $3.6 million, down 30.63% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.9 million, down from $3.6 million in the prior quarter.
- The five-year high for Accounts Payables was $9.6 million in Q4 2022, with the low at $1.9 million in Q1 2026.
- The 5-year median for Accounts Payables is $5.3 million (2022), against an average of $5.6 million.
- The sharpest annual moves came in 2023 and 2026: Accounts Payables jumped 58.67% in 2023, then plunged 62.2% in 2026.
- Tenaya Therapeutics' Accounts Payables stood at $9.6 million in 2022, then tumbled by 41.22% to $5.6 million in 2023, then fell by 8.31% to $5.2 million in 2024, then tumbled by 30.63% to $3.6 million in 2025, then tumbled by 46.55% to $1.9 million in 2026.
- Business Quant data shows TNYA's Accounts Payables at $1.9 million in Q1 2026, $3.6 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.90 Mn |
| Mar 31, 2026 | 1.91 Mn |
| Dec 31, 2025 | 3.58 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 5.16 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 6.66 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Sep 30, 2023 | 5.90 Mn |
| Jun 30, 2023 | 8.48 Mn |
| Mar 31, 2023 | 7.43 Mn |
| Dec 31, 2022 | 9.58 Mn |
| Sep 30, 2022 | 5.31 Mn |
| Jun 30, 2022 | 5.35 Mn |
| Mar 31, 2022 | 8.89 Mn |
| Dec 31, 2021 | 10.72 Mn |
| Sep 30, 2021 | 6.17 Mn |